arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ANI PHARMACEUTICALS INC

ANIP
$69.67 ▼ -1.99 (-2.78%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Bullish
auto_awesome

Analytical Summary

ANI PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.5B
Dividend Yield —
Revenue Growth 25.9% ↗
Op. Margin 15.2% ↘
ROIC 3.1% ↘
FCF / Share $2.53 →
Trailing P/E 63.9x
Price / Book 2.5x
FCF Yield 3.6%
Debt / Equity 0.47
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$266.04M
↑ +25.9% —
Net Income Profit after all expenses
$24.71M
↑ +189.1% —
Operating Margin Operating profit as % of sales
15.2%
↓ -7.1% 62th
FCF / Share Free cash flow per share
$2.53
↑ +1.3% —
Long-Term Debt Long-term obligations
$280.15M
↓ -2.0% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
68
Returns
79
Financial Health ↓
58
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters